What are the pharmacokinetics and pharmacodynamics of sertraline?

Pharmacokinetics and Pharmacodynamics of Sertraline

Sertraline is a selective serotonin reuptake inhibitor (SSRI) with a 26-hour elimination half-life, requiring approximately one week to reach steady-state plasma levels, and demonstrates linear dose-proportional pharmacokinetics across the 50-200 mg dose range. 1

Pharmacodynamics

Mechanism of Action

Sertraline's therapeutic effect stems from potent and selective inhibition of presynaptic serotonin reuptake in the CNS, increasing serotonin availability at the synaptic cleft 1. This blockade triggers a cascade over time:

• Downregulation of inhibitory serotonin autoreceptors
• Heightened serotonergic neuronal firing rate
• Increased serotonin release

This multistep process explains the delayed onset of therapeutic effect 2.

Receptor Profile

Sertraline demonstrates minimal affinity for other receptor systems, including:

• Adrenergic (α1, α2, β)
• Cholinergic
• GABA
• Dopaminergic
• Histaminergic
• Benzodiazepine receptors

This selective profile accounts for its favorable side effect profile compared to older antidepressants 1.

Time Course of Response

The pharmacodynamic profile follows a logarithmic model 2:

• Statistically (but not clinically) significant improvement: within 2 weeks
• Clinically significant improvement: by week 6
• Maximal improvement: week 12 or later

This profile supports slow up-titration to avoid exceeding the optimal dose 2.

Pharmacokinetics

Absorption and Distribution

• Peak plasma concentrations (Cmax): 4.5-8.4 hours post-dosing 1
• Bioavailability: Oral solution and tablets are bioequivalent
• Food effect: Slightly prolongs Tmax from 5.9 to 7 hours (clinically insignificant) 1
• Protein binding: 98% bound to serum proteins 1

Metabolism

Sertraline undergoes extensive first-pass metabolism 1:

• Primary pathway: N-demethylation to N-desmethylsertraline
• Key enzymes: CYP2C19 (primary for α-hydroxy sertraline ketone formation) and CYP2B6 (primary for N-desmethylsertraline formation) 3, 4, 5
• N-desmethylsertraline characteristics:
  • Half-life: 62-104 hours
  • Substantially less active than parent compound
  • Accumulates to higher concentrations than sertraline at steady state 1

Elimination

• Half-life: Approximately 26 hours (range: 22-36 hours) 1, 6
• Steady-state: Achieved after approximately 7 days of once-daily dosing 1
• Accumulation: Two-fold compared to single dose with repeated dosing 1
• Excretion:
  • 40-45% in urine (unchanged sertraline not detectable)
  • 40-45% in feces (12-14% unchanged sertraline) 1

Special Populations

Pediatric patients (6-17 years): 1

• 6-12 years: Higher AUC (3107 ng-hr/mL) and Cmax (165 ng/mL), largely due to lower body weights
• 13-17 years: Lower AUC (2296 ng-hr/mL) and Cmax (123 ng/mL)
• No gender differences observed
• At low doses, twice-daily dosing may be required in youth 2

Pharmacogenetic Considerations

CYP2C19 and CYP2B6 polymorphisms significantly influence sertraline pharmacokinetics 3, 4, 5:

• CYP2C19 poor metabolizers: ~90% reduction in α-hydroxy sertraline ketone formation, higher AUC and half-life 3, 4
• CYP2C19*17 carriers: Decreased AUC and half-life 3
• CYP2B6 poor metabolizers: 21.5% reduced N-desmethylsertraline formation 4
• CYP2D6 has minimal effect on sertraline metabolism 3

However, current guidelines state there is no clear role for pharmacogenomic testing in medication selection, though this may change as evidence accumulates 2.

Drug Interactions

Sertraline has a relatively favorable drug interaction profile 2:

• Mild CYP2D6 inhibition: May interact with drugs metabolized by CYP2D6 2
• Minimal effect on CYP1A2, CYP3A4, CYP2C9, CYP2C19 2
• Contraindicated with MAOIs: Risk of serotonin syndrome 2
• High protein binding: May displace other highly protein-bound drugs, though clinical significance is limited 1

Therapeutic Concentration Range

Optimal therapeutic concentrations appear to be 35-65 ng/mL based on real-world clinical response data 7:

• Concentrations <25 ng/mL associated with non-response
• Responders showed median 39 ng/mL (IQR: 25-62)
• Patients with psychotic depression required higher concentrations (median 67 ng/mL)

Wide interindividual variability exists: Steady-state concentrations vary up to 15-fold in patients receiving 50-150 mg/day 6.

Dosing Implications

For shorter half-life SSRIs like sertraline, dose adjustments should occur at 1-2 week intervals (compared to 3-4 weeks for fluoxetine) 2. This accounts for the time to reach steady-state and allows adequate assessment of response before escalation.

Discontinuation syndrome risk: Sertraline has been associated with discontinuation syndrome due to its relatively shorter half-life compared to fluoxetine 2. Gradual tapering is recommended when discontinuing treatment.